Author

Falconer K

17 décembre 2014
La charge de morbidité future de l'infection par le virus de l'hépatite C en Suède et l'impact des différentes stratégies de traitement
Summary Objective Recently, new highly effective direct-acting antivirals (DAAs) against hepatitis C virus (HCV) were introduced. Whether these will alleviate the anticipated increase of liver disease burden in Sweden is unknown, partly because high costs may restrict the use. The objectives were to model the HCV epidemic in Sweden, the burden of disease, and the […]

En savoir plus
5 mai 2014
Stratégies pour gérer le fardeau de la maladie du virus de l'hépatite C (VHC)
Summary The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis […]

En savoir plus
5 mai 2014
La charge de morbidité actuelle et future de l'infection par le virus de l'hépatite C (VHC) avec le paradigme de traitement actuel
Summary The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modeling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, […]

En savoir plus
5 mai 2014
Épidémiologie historique du virus de l'hépatite C (VHC) dans certains pays
Summary Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For […]

En savoir plus